Completed PHASE2 INTERVENTIONAL 1-arm NCT00226811

An International Phase 2 Study Of SU011248 In Patients With Advanced / Metastatic Gastric Cancer Failing Chemotherapy

An Open Label International Multi-Center Phase 2 Activity And Safety Study Of SU011248 In Patients With Advanced / Metastatic Gastric Cancer Progressing Or Recurring After One Prior Chemotherapy

Sponsor: Pfizer

Conditions Stomach Neoplasms

Interventions Sunitinib

Updated 7 times since 2017 Last updated: Mar 10, 2015 Started: Jan 31, 2006 Primary completion: May 31, 2008 Completion: May 31, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00226811, this PHASE2 trial focuses on Stomach Neoplasms and remains completed. Sponsored by Pfizer, it has been updated 7 times since 2006, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Jan 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Pfizer

Data source: Pfizer

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Ancona, Italy , Beijing, China , Chuo-ku, Japan , Genova, Italy , Guangzhou, China , Hong Kong, Hong Kong , Kashiwa, Japan , Kwei-Shan, Taiwan , Nanjing, China , Porto, Portugal and 4 more locations